Aqualax85 gm

Aqualax is an osmotic laxative with the following evidence-based uses:

Established / Approved Uses

• Occasional constipation: Over-the-counter Aqualax 3350 powder for oral solution is approved for short-term relief of occasional constipation, typically producing a bowel movement within 1 to 3 days.
• Bowel preparation before colonoscopy: Higher-dose, specifically formulated Aqualax-electrolyte solutions (combined with sodium sulfate, sodium chloride, sodium bicarbonate, and/or potassium chloride) are approved for full colonic lavage prior to colonoscopy or bowel surgery.

Guideline-Supported / Commonly Used Off-Label Uses

• Chronic idiopathic constipation: Daily low-dose Aqualax is widely recommended by gastroenterology guidelines (e.g., American College of Gastroenterology) as a first-line osmotic laxative for chronic constipation.
• Fecal impaction and pediatric functional constipation: High-dose, short-course Aqualax disimpaction regimens followed by lower daily maintenance doses are supported by pediatric gastroenterology guidance (e.g., NASPGHAN/ESPGHAN), used under physician supervision.

Aqualax is not an antibiotic and has no role in treating infections.

Each sachet or bottle of Polyethylene Glycol for oral solution typically contains Polyethylene Glycol 3350 (a high molecular weight, inert polymer) as the active ingredient, supplied as a powder for reconstitution. Bowel-preparation formulations combine Polyethylene Glycol 3350 with electrolytes such as sodium sulfate, sodium chloride, sodium bicarbonate, and/or potassium chloride to maintain fluid and electrolyte balance during full colonic lavage. Common strengths include 17 g single-dose sachets (for occasional constipation) and larger multi-liter kits (for bowel preparation).

Aqualax is a high molecular weight, non-absorbable polymer used medically as an osmotic laxative and bowel-cleansing agent. It works locally within the intestinal lumen without being significantly absorbed into the bloodstream, making it a widely used option for both occasional constipation and colonoscopy preparation. Aqualax is available as a powder that is dissolved in water or another beverage before ingestion.

Aqualax belongs to the therapeutic class of osmotic laxatives and, in higher-dose electrolyte formulations, is classified as a bowel evacuant / colonic lavage solution.

Mechanism of Action

Polyethylene Glycol is a large, inert polymer that is poorly absorbed from the gastrointestinal tract. It acts as an osmotic agent, causing water to be retained within the lumen of the colon. This increases the water content and volume of stool, softening it and stimulating peristalsis, which promotes a bowel movement. At higher doses used for bowel preparation, the large volume of retained fluid produces rapid, complete evacuation of the colon.

Pharmacokinetics

Polyethylene Glycol is minimally absorbed systemically; the vast majority of an ingested dose passes through the gastrointestinal tract unchanged and is excreted in the stool, with onset of action typically within 1 to 3 days for low-dose regimens and within a few hours for high-dose bowel-preparation regimens.

Aqualax powder should be measured accurately (using the provided cap or dosing device) and dissolved completely in 120–240 mL of water, juice, coffee, tea, or another beverage of any temperature before drinking. It may be taken with or without food. Do not use starch-based food thickeners with Aqualax, and do not consume the solution if clumping, gelling, or thickening occurs. For bowel-preparation formulations, follow the specific timing (single-dose or split-dose) instructed by the physician or product label.

Clinically significant interactions with Aqualax are uncommon because it is minimally absorbed, but the following are recognized:

• Oral medications: Because Aqualax increases intestinal fluid and transit, it may reduce the absorption of other oral drugs taken at the same time; other medications should generally be taken at least 1–2 hours apart from Aqualax dosing.
• Electrolyte-affecting drugs (bowel-preparation formulations only): Diuretics, ACE inhibitors, angiotensin receptor blockers, and other drugs affecting renal function or electrolyte balance may have additive effects with electrolyte-containing Aqualax bowel-preparation solutions, increasing the risk of fluid or electrolyte disturbance; use with caution and monitor as advised by a physician.

Side effects of Aqualax are generally mild and dose-related.

• Common: Abdominal bloating, cramping, flatulence, nausea, and loose or watery, more frequent stools.
• Less common, more often with bowel-preparation doses: Vomiting, abdominal fullness, and transient electrolyte imbalance (see Precautions and Warnings and Use in Special Populations).
• Rare: Hypersensitivity reactions.

Pregnancy: Because Aqualax is minimally absorbed systemically, it is generally considered a low-risk option for constipation during pregnancy; however, it should be used only if clearly needed and as directed by a physician, since well-controlled human safety data remain limited. Lactation: Aqualax is not expected to pass into breast milk in clinically significant amounts due to its negligible systemic absorption, but a physician should be consulted before use while breastfeeding.

Use Aqualax with caution in the following situations:

• Renal impairment: Patients with kidney disease should use Aqualax, especially electrolyte-containing bowel-preparation formulations, only under medical supervision due to the risk of fluid and electrolyte disturbances.
• Electrolyte disturbances: Excessive or prolonged use, or use of bowel-preparation formulations in vulnerable patients (elderly, renal or cardiac impairment), can cause clinically significant electrolyte imbalance or dehydration.
• Undiagnosed abdominal symptoms: Ask a physician before use if experiencing nausea, vomiting, abdominal pain, or a sudden change in bowel habits lasting more than 2 weeks.
• Duration of use: Not intended for long-term use without medical guidance beyond the labeled duration; stop and consult a physician if rectal bleeding occurs, diarrhea develops, or symptoms worsen.
• Inflammatory bowel disease: Use with caution and physician guidance in patients with ulcerative colitis or other significant bowel disease.

Overdose with Aqualax may cause severe diarrhea, vomiting, dehydration, and electrolyte imbalance, particularly with the higher-dose electrolyte-containing formulations. If an overdose of Aqualax is suspected, seek immediate medical attention or contact a poison control center; supportive care and correction of fluid/electrolyte disturances should be provided by a healthcare professional. Do not attempt specific home treatment beyond seeking prompt medical advice.

Store Aqualax at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Once reconstituted, the solution should generally be used promptly as directed on the product label.

Renal Impairment

Use Aqualax, particularly electrolyte-containing formulations, with caution and medical supervision in patients with renal impairment due to the risk of fluid and electrolyte disturbances (see Precautions and Warnings).

Hepatic Impairment

No specific dose adjustment of Aqualax is established for hepatic impairment; use as clinically directed.

Elderly

Elderly patients, especially those with reduced renal function or on multiple medications, should use Aqualax under medical guidance, with attention to hydration and electrolyte status.

Pediatric Use

See Pediatric Uses.

For occasional constipation, Aqualax should generally be used for no more than 7 days unless a physician directs longer treatment. For chronic constipation, longer-term daily use of Aqualax may be appropriate under physician supervision. Bowel-preparation formulations of Aqualax are intended for single-course use as directed before the procedure.

Aqualax powder must be reconstituted before use: dissolve the measured dose completely in 120–240 mL (4–8 oz) of water or another beverage of any temperature, stirring until fully dissolved, and drink promptly. For bowel-preparation kits, reconstitute the entire container as instructed on the product label, typically to a specified total volume with water.

Polyethylene Glycol is classified under Laxatives, specifically the Osmotic Laxatives subclass, and under Bowel Evacuants/Colonic Lavage Solutions for its higher-dose bowel-preparation formulations.

Polyethylene Glycol works by osmotically retaining water within the intestinal lumen, which softens the stool and increases stool volume, thereby stimulating bowel motility and producing a bowel movement without significant systemic absorption.

Aqualax is not FDA-approved for unsupervised use in children 16 years of age and younger under the standard over-the-counter labeling, and safety and efficacy for self-directed use in this age group have not been established under that labeling. However, under physician supervision, weight-based Aqualax regimens are widely used and supported by pediatric gastroenterology guidance (e.g., NASPGHAN/ESPGHAN) for functional constipation and fecal disimpaction in children. Any use of Aqualax in children should be directed and monitored by a physician.